News

Working Groups Seeking Online Curriculum Consultant

The Stop TB Partnership Working Group on New TB Vaccines (WGNV), Working Group on New TB Drugs (WGND), and New Diagnostics Working Group (NDWG) are developing an online course specifically designed for advocates and affected communities to provide a base of knowledge in TB research and to generate interest and engagement in TB research advocacy. The New Tools Working Groups (WGs) are seeking an online curriculum consultant/ writer for the course. The consultant will contract with the host organization for each of the WGs. 

The overall goal of this project is to develop an online curriculum that will provide participants with a basic working knowledge and understanding of issues in TB research for vaccines, drugs, and diagnostics, even with no prior knowledge and experience with TB research. The content will consist of basics aimed at advocates, individuals from affected communities and other stakeholders interested in new tool research and development. 

An RFP for the project can be found at this link

Proposals are due Thursday, December 31st, 2020

Please address your proposal and any inquiries to: 
Jennifer Woolley 
Secretariat 
Working Group on New TB Vaccines 
wgnv@newtbvaccines.org  
 

 

More News
30 Mar 2021
Médecins Sans Frontières (MSF) published a press release on World TB Day 2021 announcing their clinical trial, TB-Practecal , investigating novel treatment for MDR-TB has stopped enrolling earlier than originally planned due to promising results. The trial's independent data safety and monitoring...
3 Feb 2021
Last week, the World Health Organization (WHO) held a consultation to discuss the definition of extensively drug resistant (XDR) tuberculosis. The meeting was held to discuss novel treatment regimens and diagnostics for drug-resistant TB and determine its impact on the definition of XDR-TB. The...
22 Oct 2020
On Thursday, October 21st, 2020, the U.S. Centers for Disease Control and Prevention's (CDC) TB Trials Consortium (TBTC) announced results from their Phase 3, open-label trial: Study 31/A5349. The clinical trial identified a 4-month drug regimen composed of high-dose rifapentine, moxyifloxacin,...